Roflumilast for the Treatment of Seborrheic Dermatitis: A Review.

Division

North Florida

Hospital

Capital Regional Medical Center

Document Type

Case Report

Publication Date

3-1-2025

Keywords

Humans, Dermatitis, Seborrheic, Aminopyridines, Cyclopropanes, Benzamides, Administration, Cutaneous

Disciplines

Dermatology | Medicine and Health Sciences | Skin and Connective Tissue Diseases

Abstract

Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of Malassezia, sebocyte activity, impaired immunity, and environmental influences. Topical antifungals, corticosteroids, and calcineurin inhibitors are the current mainstay treatment of SD. Recent clinical trials have validated the efficacy of non-steroidal roflumilast 0.3% foam for the treatment of SD. In this review, we analyze the safety and efficacy profile of roflumilast 0.3% foam.

Publisher or Conference

Skin Therapy Letter

Link to Full Text

Share

COinS